Page 10 - Zydus Cadila

Zydus gets USFDA nod for drugs treating fungal infections, skin disorder

Company will manufacture Fluconazole tablets at its Baddi facility

Zydus adds muscle with US buy

String of brand buying in India to give it more diversified portfolio

Zydus Cadila acquires US-based specialty drugs player Sentynl

With this acquisition, Zydus makes a foray into the specialty pain market in the US valued at $8 bn

Zydus Cadila acquires US-based Sentynl Therapeutics

The transaction will be earnings per share accretive

Zydus Cadila open for buyouts in the US

Denies reports of looking to acquire Sentynl Therapeutics

Zydus gets USFDA nod for chemotherapy drug

The drug will be produced at the group's manufacturing facility in Ahmedabad

Zydus Cadila gets USFDA nod for cancer drug

Cadila group now has more than 105 approvals and has so far filed nearly 275 ANDAs since 2003-04

Zydus Cadila CMD Pankaj Patel becomes new FICCI president

Will take over from Harshavardhan Neotia, Chairman of Ambuja Neotia Group

After chikungunya, Zydus to now co-develop malaria drug

The scale-up of control measures including medicines has saved the lives of more than six million people since 2000

Zydus gets FDA nod for diabetes drug

The company today informed in a statement that it has received the nod from the US drug regulator to market the drug in strengths of 60 mg and 120 mg

Zydus inks pact with Medicines Patent Pool for Hepatitis-C drug

The agreement sub-licences Zydus to produce and sell daclatasvir in 112 low and middle income countries

Zydus acquires two ANDAs from Teva

The acquisition of these ANDAs is contingent on the closing of the Teva-Allergan Generics transaction

Zydus to go ahead with clinical trial of Saroglitazar

The company will be allowed to evaluate Saroglitazar in strengths of 1mg, 2mg and 4mg versus placebo

Zydus to start phase-II clinical trial for saroglitazar in US

This trial will be conducted across several medical sites in the US

Zydus gets FDA nod to market anti-fungal drug

The drug had estimated sales of around $92.8 million in 12 months to March 2016, as per IMS data

Zydus Cadila gets USFDA's final nod for fungal treatment drug

The drug will be produced at the groups formulations manufacturing facility at Baddi

Zydus Cadila Q4 net rises 11%

Consolidated total income from operations during the quarter stood at Rs 2,449 crore

Zydus Cadila gets tentative USFDA nod for cancer cure

The group now has more than 100 approvals and has filed over 280 ANDAs.

Zydus Cadila gets USFDA nod for anti-diabetics tablets

Tthe group's formulations manufacturing site at Baddi will be producing the drug for the US market

Zydus to commence supplies to US from facility at Ahmedabad SEZ

Receives approval for Doxycycline Capsules USP